Clinical Trials Browser

Phase 2/3 × Colorectal Neoplasms × 1 year × Clear all

NCT06280495 2026-04-20

Neoadjuvant Serplulimab & Bevacizumab With FOLFOX vs. FOLFOX Alone in RAS/BRAF WT, pMMR/MSS CRC Patients

Phase 2/3 Recruiting

Gastrointestinal

Colorectal Neoplasms

NCT07509398 2026-04-03

FMT Combined With Standard First-Line Therapy in Initially Unresectable Colorectal Cancer

Phase 2/3 Not yet recruiting

Gastrointestinal

Neoplasm Metastasis, Colorectal Neoplasms

NCT07221357 2026-03-31

A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer

Phase 2/3 Recruiting

Gastrointestinal

Colorectal Neoplasms

NCT02758951 2026-03-24

CAIRO6

Phase 2/3 Active not recruiting

GastrointestinalGynecologic

Hyperthermia, Colonic Neoplasms, Peritoneal Neoplasms, Colorectal Neoplasms

NCT07440290 2026-02-27

DETERMINE

Phase 2/3 Not yet recruiting

CNSEndocrineGastrointestinalGynecologicHead & NeckLymphoidMyeloidOther hematologic neoplasmPlasma cellThoracic

Thyroid Cancer, Papillary, Carcinoma, Non-Small-Cell Lung, Gastrointestinal Neoplasms, Glioma, Histiocytosis, Langerhans-Cell, Laryngeal Neoplasms, Lymphoproliferative Disorders, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Ovarian Neoplasms, Colorectal Neoplasms, Hematologic Neoplasms, Erdheim-Chester Disease, Thyroid Carcinoma, Anaplastic

NCT00208260 2026-02-05

Intensified Chemotherapy in CRC After Resection of Liver Metastases

Phase 2/3 Completed

Gastrointestinal

Colorectal Neoplasms

NCT04137107 2026-01-26

Duloxetine to Prevent Oxaliplatin-Induced Peripheral Neuropathy in Patients With Stage II-III Colorectal Cancer

Phase 2/3 Active not recruiting

Gastrointestinal

Colorectal Neoplasms

NCT07321847 2026-01-07

INJECTABL-3

Phase 2/3 Not yet recruiting

Gastrointestinal

Neoplasm Metastasis, Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT05786716 2025-12-02

DETERMINE

Phase 2/3 Recruiting

DermatologicGastrointestinalGenitourinaryGynecologicHead & NeckOther hematologic neoplasmThoracic

Urinary Bladder Neoplasms, Gallbladder Neoplasms, Lung Neoplasms, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Salivary Gland Neoplasms, Skin Neoplasms, Colorectal Neoplasms, Hematologic Neoplasms

NCT05768178 2025-11-24

DETERMINE

Phase 2/3 Recruiting

CNSDermatologicEndocrineGastrointestinalGynecologicHead & NeckMyeloidOther hematologic neoplasmPlasma cellThoracic

Thyroid Cancer, Papillary, Carcinoma, Non-Small-Cell Lung, Glioma, Laryngeal Neoplasms, Melanoma, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Ovarian Neoplasms, Colorectal Neoplasms, Hematologic Neoplasms, Erdheim-Chester Disease, Thyroid Carcinoma, Anaplastic

NCT05770102 2025-11-24

DETERMINE

Phase 2/3 Recruiting

DermatologicGastrointestinalGynecologicLymphoid

Lymphoproliferative Disorders, Melanoma, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Colorectal Neoplasms, Endometrial Neoplasms

NCT05945901 2025-11-18

A Phase II/III Study of HR070803 in Combination With Oxaliplatin, 5-fluorouracil, Calcium Folinate and Bevacizumab Versus FOLFOX in Combination With Bevacizumab for First-line Treatment of Advanced Colorectal Cancer

Phase 2/3 Active not recruiting

Gastrointestinal

Colorectal Neoplasms

NCT07219238 2025-10-21

Study to Evaluate the Diagnostic Performance of GEH300079 (68Ga) Injection PET/CT for Detection of PC in Patients With Colorectal, Gastric, Ovarian, or Pancreatic Cancers (PERISCOPE)

Phase 2/3 Not yet recruiting

GastrointestinalGynecologic

Ovarian Neoplasms, Pancreatic Neoplasms, Peritoneal Neoplasms, Stomach Neoplasms, Colorectal Neoplasms

NCT06958419 2025-08-07

Node-Sparing Short-Course Radiotherapy Plus Chemotherapy, Bevacizumab and PD-1 Inhibitor in Metastatic pMMR/MSS Colorectal Cancer (MODIFI-CRC)

Phase 2/3 Recruiting

Gastrointestinal

Colorectal Neoplasms

NCT03326791 2025-07-31

ASAC

Phase 2/3 Active not recruiting

Gastrointestinal

Colorectal Neoplasms

NCT06441565 2025-07-30

Fruquintinib With or Without HAI-FOLFOX for Refractory Colorectal Cancer

Phase 2/3 Recruiting

Gastrointestinal

Colorectal Neoplasms

NCT04856787 2025-05-18

A Clinical Studyf of SHR-1701 or Placebo in Combination With BP102 and XELOX in the First-line Treatment of mCRC

Phase 2/3 Terminated

Gastrointestinal

Colorectal Neoplasms

NCT05141721 2025-05-16

A Study of a Patient-Specific Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer

Phase 2/3 Active not recruiting

Gastrointestinal

Colorectal Neoplasms

NCT06959693 2025-05-06

A Clinical Study to Evaluate the Efficacy and Safety of Envafolimab Combined With Cetuxima-βand mFOLFOX6 in Patients With MSS, RAS/BRAF Wild-Type Metastatic Colorectal Cancer (mCRC)

Phase 2/3 Not yet recruiting

Gastrointestinal

Colorectal Neoplasms